AngioDynamics (ANGO) Tops Q1 EPS by 2c, Updates Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Oil slips as Saudi Arabia offers more crude via Oman
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Exclusive-SK Hynix in talks with Intel about deal to make memory chips in US for the first time, sources say
- Trade the FOMC: How stocks tend to perform on Fed hike days
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- Bernstein on Crypto: 'Clarity fails - what next?'
AngioDynamics Reports Fiscal 2022 First Quarter Financial Results; Updates Guidance
September 30, 2021 7:00 AM EDTFiscal 2022 First Quarter Highlights
Net sales of $77.0 million increased 9.6% compared to the prior-year quarter Gross margin of 52.1% increased 120 basis points year over year GAAP loss per share of $0.18, and adjusted loss per share of $0.02 The Company commenced a Limited Market Release of its AlphaVac Mechanical Thrombectomy device in SeptemberLATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and... More
